Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ARGX stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Thomas Smith has given his Buy rating due to a combination of factors, primarily driven by Argenx Se’s impressive financial performance and strategic advancements. The company reported robust second-quarter financial results, with Vyvgart’s net revenue significantly surpassing both sell-side and buy-side expectations. This strong revenue growth is attributed to the expansion of Vyvgart across various presentations and indications, with a notable number of patients being treated globally.
Additionally, the recent launch of Vyvgart Hytrulo PFS, which allows for patient self-administration, is progressing well, further enhancing the product’s market potential. Management’s insights into Vyvgart’s gross-to-net dynamics and consistent revenue contribution per patient reinforce the company’s strong market position. Furthermore, the anticipation of multiple Phase 3 pivotal readouts in the coming months for Vyvgart and Argenx’s emerging immunology pipeline supports the view that Argenx remains a core holding in the immunology sector.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $778.00 price target.